BRPI0918103A2 - "método para o tratamento da dor em um indivíduo" - Google Patents

"método para o tratamento da dor em um indivíduo"

Info

Publication number
BRPI0918103A2
BRPI0918103A2 BRPI0918103A BRPI0918103A BRPI0918103A2 BR PI0918103 A2 BRPI0918103 A2 BR PI0918103A2 BR PI0918103 A BRPI0918103 A BR PI0918103A BR PI0918103 A BRPI0918103 A BR PI0918103A BR PI0918103 A2 BRPI0918103 A2 BR PI0918103A2
Authority
BR
Brazil
Prior art keywords
individual
treating pain
pain
treating
Prior art date
Application number
BRPI0918103A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew David Cook
John Allan Hamilton
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of BRPI0918103A2 publication Critical patent/BRPI0918103A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0918103A 2008-12-22 2009-12-21 "método para o tratamento da dor em um indivíduo" BRPI0918103A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13968708P 2008-12-22 2008-12-22
US16449109P 2009-03-30 2009-03-30
PCT/AU2009/001671 WO2010071923A1 (en) 2008-12-22 2009-12-21 Pain treatment

Publications (1)

Publication Number Publication Date
BRPI0918103A2 true BRPI0918103A2 (pt) 2016-07-05

Family

ID=42286785

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918103A BRPI0918103A2 (pt) 2008-12-22 2009-12-21 "método para o tratamento da dor em um indivíduo"

Country Status (12)

Country Link
US (3) US8475796B2 (enExample)
EP (2) EP3381471B1 (enExample)
JP (3) JP5674677B2 (enExample)
KR (1) KR101761324B1 (enExample)
CN (2) CN102256621B (enExample)
AU (2) AU2009329811B2 (enExample)
BR (1) BRPI0918103A2 (enExample)
CA (1) CA2747206C (enExample)
ES (2) ES2978209T3 (enExample)
HK (2) HK1255046A1 (enExample)
RU (2) RU2630969C2 (enExample)
WO (1) WO2010071923A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381471B1 (en) 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
KR20210021153A (ko) * 2012-09-20 2021-02-24 모르포시스 아게 류마티스 관절염에 대한 치료
CN104995210A (zh) * 2012-09-20 2015-10-21 莫弗系统股份公司 类风湿关节炎的治疗
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
DK3328887T3 (da) * 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN120093288B (zh) * 2025-05-08 2025-07-11 中国农业大学烟台研究院 一种牲畜生理行为监测方法及系统

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234479A (en) * 1989-07-14 1992-03-26 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus, antibodies, hybridomas and pharmaceutical compositions containing anti-idiotypic antibodies
DK0486572T3 (da) 1989-08-11 1998-05-04 Amrad Corp Ltd Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
EP0673389A1 (en) * 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
WO2003035048A2 (en) 2001-10-26 2003-05-01 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040241755A1 (en) 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ES2465141T3 (es) 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
ES2918209T3 (es) * 2005-05-18 2022-07-14 Morphosys Ag Anticuerpos anti-GM-CSF y usos a partir de los mismos
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009517069A (ja) 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
JP2010527939A (ja) 2007-05-23 2010-08-19 シーアールシー・フォー・アズマ・アンド・エアウェイズ・リミテッド 中和抗体
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
DK2376121T4 (da) 2008-12-22 2021-08-16 Univ Melbourne Slidgigtbehandling
EP3381471B1 (en) * 2008-12-22 2024-03-20 The University of Melbourne Pain treatment
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
ES2978209T3 (es) 2024-09-09
JP6147704B2 (ja) 2017-06-14
KR20110117659A (ko) 2011-10-27
US9352034B2 (en) 2016-05-31
CN102256621A (zh) 2011-11-23
JP2012512814A (ja) 2012-06-07
CA2747206A1 (en) 2010-07-01
HK1255227A1 (en) 2019-08-09
RU2630969C2 (ru) 2017-09-15
US20110287027A1 (en) 2011-11-24
EP2387418B1 (en) 2018-06-13
US9834599B2 (en) 2017-12-05
CN108014335A (zh) 2018-05-11
RU2712166C2 (ru) 2020-01-24
US8475796B2 (en) 2013-07-02
US20160311896A1 (en) 2016-10-27
CA2747206C (en) 2018-04-24
AU2016200267A1 (en) 2016-02-11
JP2014224123A (ja) 2014-12-04
AU2016200267B2 (en) 2017-09-07
EP2387418A4 (en) 2013-07-17
WO2010071923A1 (en) 2010-07-01
JP5674677B2 (ja) 2015-02-25
EP3381471A1 (en) 2018-10-03
RU2016102346A (ru) 2018-11-20
EP3381471B1 (en) 2024-03-20
KR101761324B1 (ko) 2017-07-25
RU2016102346A3 (enExample) 2019-07-29
CN102256621B (zh) 2017-12-12
RU2011127333A (ru) 2013-01-27
EP3381471C0 (en) 2024-03-20
US20130243791A1 (en) 2013-09-19
ES2685895T3 (es) 2018-10-15
HK1255046A1 (zh) 2019-08-02
AU2009329811A1 (en) 2010-07-01
JP2017149740A (ja) 2017-08-31
EP2387418A1 (en) 2011-11-23
AU2009329811B2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
BRPI0906099A2 (pt) "método de tratamento do câncer em um indivíduo"
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
BRPI0916049A2 (pt) "dispositivo para tratamento da cavidade dental e método para tratamento da cavidade dental"
BRPI0814776A2 (pt) Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PT3058875T (pt) Sistema para tratamento cosmético e imagiologia
BRPI0818963A2 (pt) Conjugado anticorpo-molécula parceira e método para tratar câncer em um indivíduo
BRPI0819075A2 (pt) Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
BRPI0906328A2 (pt) "método para reduzir sulfeto de hidrogênio em asfalto, método para tratar asfalto e composição sequestrante de sulfeto de hidrogênio"
BRPI0815283A2 (pt) Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0916472A2 (pt) dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento
EP2334315A4 (en) MEANS AND METHOD OF TREATMENT TREATMENT
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0812585A2 (pt) Aparelho de tratamento de redução e método de tratamento de redução
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0923534A2 (pt) composição e método para tratamento de doenças de pele
BRPI0923662A2 (pt) composições tópicas contendo melicope hayesii e um método para o tratamento da pele
BRPI0905996A2 (pt) "método e aparelho para secagem contínua"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.